A5026926354- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- Peptidase Inhibition and Analysis
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Radiopharmaceutical Chemistry and Applications
- Cancer Genomics and Diagnostics
- Chemotherapy-related skin toxicity
- Monoclonal and Polyclonal Antibodies Research
- Breast Lesions and Carcinomas
- Chemotherapy-induced cardiotoxicity and mitigation
- Gene expression and cancer classification
- Bone health and treatments
- Cancer Diagnosis and Treatment
- IL-33, ST2, and ILC Pathways
- BRCA gene mutations in cancer
- Kruppel-like factors research
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Chronic Lymphocytic Leukemia Research
- PI3K/AKT/mTOR signaling in cancer
- Glutathione Transferases and Polymorphisms
The University of Texas MD Anderson Cancer Center
2013-2024
Breast Cancer Care
1995-2012
Okayama University
2010-2012
Beth Israel Deaconess Medical Center
2011
Texas Oncology
2003-2010
Institut Gustave Roussy
2006-2010
Hospital of Prato
2010
Medical University of Graz
2010
Institut Jules Bordet
2009-2010
National Cancer Institute
2010
Purpose The objective of this study was to determine whether the addition trastuzumab chemotherapy in neoadjuvant setting could increase pathologic complete response (pCR) rate patients with human epidermal growth factor receptor 2 (HER2) –positive disease. Patients and Methods Forty-two HER2-positive disease operable breast cancer were randomly assigned either four cycles paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide or same simultaneous weekly for 24 weeks. primary...
We developed a multigene predictor of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil-doxorubicin-cyclophosphamide (T/FAC) chemotherapy assessed its predictive accuracy on independent cases.One hundred thirty-three patients with stage I-III breast cancer were included. Pretreatment gene expression profiling was performed oligonecleotide microarrays fine-needle aspiration specimens. predictors pCR from 82 cases 51 cases.Overall rate 26% in both cohorts....
PURPOSE: To evaluate the safety and efficacy of weekly docetaxel plus trastuzumab in women with HER-2–overexpressing metastatic breast cancer. Efficacy was correlated serum HER-2 extracellular domain (ECD) levels. PATIENTS AND METHODS: Thirty cancer were treated as first- or second-line therapy. Both 35 mg/m 2 /wk mg/kg/wk delivered 4-week cycles consisting three treatments followed by 1 week rest. A loading dose 4 mg/kg administered day before start first cycle. RESULTS: The median...
Purpose The goal of this study was to examine the feasibility developing a multigene predictor pathologic complete response (pCR) sequential weekly paclitaxel and fluorouracil + doxorubicin cyclophosphamide (T/FAC) neoadjuvant chemotherapy regimen for breast cancer. Patients Methods All patients underwent one-time pretreatment fine-needle aspiration obtain RNA from cancer transcriptional profiling using cDNA arrays containing 30,721 human sequence clones. Analysis performed after profiling,...
PURPOSE: No standardized therapeutic interventions have been reported for patients diagnosed with breast cancer during pregnancy. Of the potential interventions, none prospectively evaluated treatment efficacy in mother or safety fetus. We present our experience use of combination chemotherapy PATIENTS AND METHODS: During past 8 years, 24 pregnant primary recurrent were managed by outpatient chemotherapy, surgery, surgery plus radiation therapy, as clinically indicated. The included...
Purpose To determine the impact a change in schedule of paclitaxel administration from once every 3 weeks to frequent would have on pathologic complete response (pCR) rate breast and lymph nodes for patients with invasive cancer treated primary systemic chemotherapy (PST). Patients Methods clinical stage I-IIIA were randomly assigned receive PST doses administered either weekly (for total 12 paclitaxel) or (four cycles), followed by four cycles fluorouracil/doxorubicin/cyclophosphamide (FAC)...
Abstract There is a clinical need to predict sensitivity of metastatic hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer endocrine therapy, targeted RNA sequencing (RNAseq) offers diagnostic potential measure both transcriptional activity functional mutation. We developed the SET ER/PR index gene expression microarray probe sets that were correlated with receptors ( ESR1 PGR ) robust preanalytical analytical influences. tested in biopsies metastastic HR+/HER2− against...
There is limited prognostic information to identify breast cancer patients who are at risk for late recurrences after adjuvant or neoadjuvant systemic therapy (AST). We evaluated the residual of recurrence and factors 2838 with stage I–III were treated AST between January 1, 1985, November 2001, remained disease free 5 years. Residual recurrence-free survival was estimated from landmark years date first last follow-up using Kaplan–Meier method. The log-rank test (two-sided) used compare...
We hypothesize that measurement of gene expression related to estrogen receptor α (ER; name ESR1) within a breast cancer sample represents intrinsic tumoral sensitivity adjuvant endocrine therapy.A genomic index for therapy (SET) was defined from genes coexpressed with ESR1 in 437 microarray profiles newly diagnosed cancer, unrelated treatment or outcome. The association SET and levels distant relapse risk evaluated microarrays ER-positive two cohorts who received 5 years tamoxifen alone as...
We examined borderline estrogen receptor (ER) -positive cancers, defined as having 1% to 10% positivity by immunohistochemistry (IHC), determine whether they show the same global gene-expression pattern and high ESR1 mRNA expression ER-positive cancers or if are more similar ER-negative cancers.ER status was determined IHC in 465 primary breast with Affymetrix U133A gene chip. compared expressions of a 106 probe set ER-associated signature score between (n = 183), 9% 25), 6), than 251)...
Abstract BACKGROUND The primary objective of this study was to determine whether addition the selective P‐glycoprotein (P‐gp) inhibitor tariquidar (XR9576) chemotherapy could induce an tumor response in patients who previously were resistant same agents. secondary objectives evaluate P‐gp expression by immunohistochemistry (IHC), functional activity transporter before and after administration with serial technetium‐99m ( 99m Tc)‐sestamibi scans, correlate those parameters clinical response....
PURPOSE: To compare prospectively the antitumor activity of single-agent paclitaxel to three-drug combination fluorouracil, doxorubicin, and cyclophosphamide (FAC) as neoadjuvant therapy in patients with operable breast cancer. PATIENTS AND METHODS: Patients T1-3N0-1M0 disease were randomized receive either (250 mg/m 2 ) 24-hour infusion or FAC standard doses at every-3-week intervals. Each patient was treated four cycles preoperative chemotherapy. Clinical response extent residual lymph...
BackgroundWe hypothesized that distinct biological processes might be associated with prognosis and chemotherapy sensitivity in the different types of breast cancers.
PURPOSE To evaluate the efficacy and safety of docetaxel in patients with paclitaxel-resistant metastatic breast cancer (MBC). PATIENTS AND METHODS Docetaxel (100 mg/m2) was administered every 3 weeks to 46 registered at four centers. Patients had previously received < or = two chemotherapy regimens for MBC. All progressive disease while receiving paclitaxel therapy. Treatment repeated until there evidence progression a maximum three cycles after best response. RESULTS Objective responses...
Abstract Introduction As part of the MicroArray Quality Control (MAQC)-II project, this analysis examines how choice univariate feature-selection methods and classification algorithms may influence performance genomic predictors under varying degrees prediction difficulty represented by three clinically relevant endpoints. Methods We used gene-expression data from 230 breast cancers (grouped into training independent validation sets), we examined 40 (five combined with eight different...
PURPOSE: To determine outcomes in local-regional control, disease-free survival, and overall survival patients with locally advanced breast cancer (LABC) who present ipsilateral supraclavicular metastases are treated combined-modality therapy. PATIENTS AND METHODS: Seventy regional stage IV LABC, which is defined by our institution as LABC adenopathy without evidence of distant disease, received treatment on three prospective trials neoadjuvant chemotherapy. All chemotherapy...
Purpose Trastuzumab resistance has been linked to activation of the phosphoinositol 3-kinase (PI3K) pathway. Phosphatase and tensin homolog (PTEN) is a dual phosphatase that counteracts PI3K function; PTEN loss leads Akt cascade downstream mammalian target rapamycin (mTOR). Preclinical studies demonstrated mTOR inhibition sensitized response trastuzumab in mice with HER2 overexpressing PTEN-deficient breast xenografts. Our trial evaluated safety efficacy combination everolimus women...
Uncontrolled studies have reported encouraging outcomes for patients with high-risk primary breast cancer treated high-dose chemotherapy and autologous hematopoietic stem cell support. We conducted a prospective randomized trial to compare standard-dose the same therapy followed by chemotherapy.Patients 10 or more positive axillary lymph nodes after surgery four cycles of (neoadjuvant) were eligible. All receive eight 5-fluorouracil, doxorubicin (Adriamycin), cyclophosphamide (FAC). Patients...
Accurate assessment of HER-2 status is necessary prior to anti-HER-2 antibody (trastuzumab) therapy for metastatic breast carcinoma. However, controversy exists regarding whether assess in the primary tumor or lesions. It also unclear can change during disease progression after chemotherapy.Breast carcinoma samples from 60 women with known both tumors and paired metastases (locoregional disease, n = 43 patients; distant 17 patients) were reviewed retrospectively. Thirty-two patients...